Daniel Barber Sells 25,000 Shares of Aquestive Therapeutics (NASDAQ:AQST) Stock

Aquestive Therapeutics, Inc. (NASDAQ:AQST) CEO Daniel Barber sold 25,000 shares of Aquestive Therapeutics stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $4.82, for a total value of $120,500.00. Following the sale, the chief executive officer directly owned 652,317 shares of the company’s stock, valued at approximately $3,144,167.94. The trade was a 3.69% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Aquestive Therapeutics Price Performance

Shares of AQST stock opened at $4.66 on Friday. Aquestive Therapeutics, Inc. has a fifty-two week low of $2.93 and a fifty-two week high of $7.55. The stock’s 50-day moving average is $4.43 and its two-hundred day moving average is $4.28. The firm has a market cap of $584.88 million, a P/E ratio of -7.17 and a beta of 1.48.

Aquestive Therapeutics (NASDAQ:AQST) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.08). The firm had revenue of $13.82 million during the quarter, compared to analyst estimates of $11.42 million. As a group, research analysts expect that Aquestive Therapeutics, Inc. will post -0.5 EPS for the current year.

Analyst Ratings Changes

A number of research analysts have recently weighed in on AQST shares. Weiss Ratings restated a “sell (d-)” rating on shares of Aquestive Therapeutics in a report on Friday, July 17th. HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Aquestive Therapeutics in a report on Monday, August 24th. Cantor Fitzgerald reissued an “overweight” rating and set a $11.00 target price on shares of Aquestive Therapeutics in a research report on Thursday, September 10th. Finally, Wall Street Zen upgraded Aquestive Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, September 12th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $9.17.

Hedge Funds Weigh In On Aquestive Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. WINTON GROUP Ltd acquired a new stake in shares of Aquestive Therapeutics in the second quarter worth $210,000. Engineers Gate Manager LP grew its stake in Aquestive Therapeutics by 20.5% in the 2nd quarter. Engineers Gate Manager LP now owns 49,879 shares of the company’s stock valued at $207,000 after buying an additional 8,496 shares during the last quarter. Wedbush Securities Inc. acquired a new position in Aquestive Therapeutics in the 2nd quarter valued at $60,000. Wellington Management Group LLP raised its holdings in Aquestive Therapeutics by 4.0% in the 2nd quarter. Wellington Management Group LLP now owns 301,647 shares of the company’s stock worth $1,255,000 after acquiring an additional 11,587 shares during the period. Finally, Beacon Pointe Advisors LLC bought a new position in Aquestive Therapeutics in the 2nd quarter worth $252,000. Institutional investors and hedge funds own 32.45% of the company’s stock.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on developing and commercializing medicines delivered through its PharmFilm technology. The company’s dissolvable oral-film platform is designed to provide alternatives to conventional tablets, capsules and injectable therapies, with potential benefits for patients who have difficulty swallowing or require rapid, convenient administration.

Aquestive’s commercial products include Exservan, an oral film formulation of riluzole for people with amyotrophic lateral sclerosis; Libervant, a buccal film formulation of diazepam for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity; and Sympazan, an oral film formulation of clonazepam for the treatment of seizures associated with Lennox-Gastaut syndrome.